mAChR M5 Inhibitors

mAChR M5 inhibitors constitute a chemical class aimed at modulating the M5 subtype of muscarinic receptors. The M5 receptor, encoded by the CHRM5 gene, is expressed predominantly in the central nervous system and is involved in modulating dopamine release and other neurotransmitter systems. While selective inhibitors for the M5 receptor are not common, several antimuscarinic agents can indirectly affect its activity. Inhibitors such as scopolamine and atropine are classical muscarinic antagonists with a broad range of activity across all muscarinic receptor subtypes. Their inhibition of M5 is part of a wider antagonistic effect on the parasympathetic system. Scopolamine, for example, binds to the acetylcholine binding site on muscarinic receptors, preventing the neurotransmitter from exerting its effect. Other agents, like pirenzepine and telenzepine, are selective for the M1 subtype but can modulate the cholinergic system in a way that impacts the functionality of M5 receptors. The changes in cholinergic transmission that result from blocking M1 receptors can have downstream effects on M5 receptors due to the interconnected nature of neuronal signaling pathways.Some compounds, such as darifenacin and 3-Quinuclidinyl benzilate, have a higher affinity for other muscarinic receptor subtypes, yet their action results in altered cholinergic neurotransmission that affects M5 receptor activity. This indirect influence arises because the various muscarinic receptors do not function in isolation but are part of a complex interplay within the nervous system. By altering the balance of muscarinic signaling, these agents can modulate the physiological processes in which the M5 receptor is involved, despite not being direct antagonists of this specific subtype.